The Bridge covers Wegovy (injection and tablets), Zepbound (KwikPen formulation only), and Foundayo the GLP-1s with FDA approval for obesity
Acceptable evidence includes any dated document or image issued within the past 30 dayssuch as a pharmacy dispensing label, electronic health-record screenshot, insurance explanation of benefits, clinical-trial visit summary, medication package showing a pharmacy sticker, refill receipt, or telehealth prescriptionprovided it clearly references a GLP-1 product (examples include semaglutide, liraglutide, dulaglutide, exenatide, lixisenatide, tirzepatide, or their brand or generic names)
66% fat for semaglutide alone
KeatonJMHellwegeJNNgMCYPalmerNDPankowJSFornageMet al
Clinical Evaluation Depth: Biomarkers, Baseline Labs, and Provider Decision-Making Both Ro and Fridays require baseline health information, but neither mandates bloodwork before the initial prescription